These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 7684099)

  • 1. [Optimal way of administration of granulocyte colony stimulating factor in the treatment of urological cancer].
    Okaneya T; Tsuruta T; Niwakawa M; Kawakami M; Kobayashi S; Ogawa A
    Nihon Hinyokika Gakkai Zasshi; 1993 Apr; 84(4):680-5. PubMed ID: 7684099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of recombinant human granulocyte colony-stimulating factor in patients receiving chemotherapy for urogenital cancer. Urological rhG-CSF Study Group.
    Aso Y; Akaza H
    J Urol; 1992 Apr; 147(4):1060-4. PubMed ID: 1372661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of methotrexate, vinblastine, doxorubicin and cisplatin plus recombinant human granulocyte-macrophage colony stimulating factors in patients with advanced transitional cell carcinoma.
    Moore MJ; Iscoe N; Tannock IF
    J Urol; 1993 Oct; 150(4):1131-4. PubMed ID: 8371371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of dose intensity on M-VAC therapy for advanced urothelial cancer.
    Miyanaga N; Akaza H; Shimazui T; Ohtani M; Koiso K
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S5-8. PubMed ID: 7527735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Granulocyte function of patients on anti-cancer chemotherapy].
    Okada H; Miyazaki J; Kamidono S
    Nihon Hinyokika Gakkai Zasshi; 1994 Jun; 85(6):958-63. PubMed ID: 7520515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. M-VEC (methotrexate, vinblastine, epirubicin, and cisplatin) with granulocyte colony-stimulating factor for the treatment of urothelial cancer: an effective and safe chemotherapy regimen.
    Igawa M; Kadena H; Ueda M; Usui T
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S1-4. PubMed ID: 7527732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial.
    Loehrer PJ; Elson P; Dreicer R; Hahn R; Nichols CR; Williams R; Einhorn LH
    J Clin Oncol; 1994 Mar; 12(3):483-8. PubMed ID: 7509853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Dose intensity in M-VAC chemotherapy with rG-CSF for metastatic transitional urothelial cancer].
    Obata K; Kobayashi H; Takaba H; Yokoi K; Hikosaka A
    Hinyokika Kiyo; 1994 Oct; 40(10):939-44. PubMed ID: 7527613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Schedule-intensified M-VAC chemotherapy for advanced urothelial cancer with recombinant human granulocyte colony stimulating factor (rhG-CSF).
    Noguchi S; Kubota Y; Shuin T; Hosaka M; Miura T; Kondoh I
    Int J Urol; 1994 Jun; 1(2):140-2. PubMed ID: 7543010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of recombinant human granulocyte colony stimulating factor in patients with transitional cell carcinoma of the urothelium receiving methotrexate, etoposide and cisplatinum combination chemotherapy].
    Miura T; Murai T; Shimura H; Kondo I
    Hinyokika Kiyo; 1993 Mar; 39(3):209-12. PubMed ID: 7685138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Colony stimulating factors in polychemotherapy of testicular tumors. A comparison between G-CSF and GM-CSF].
    Will R; Hofmockel G; Langer W; Frohmüller H
    Urologe A; 1999 May; 38(3):258-63. PubMed ID: 10407985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of dose-intensified MEC (methotrexate, epirubicin and cisplatin) chemotherapy for advanced urothelial carcinoma: a prospective randomized trial comparing MEC and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin). Japanese Urothelial Cancer Research Group.
    Kuroda M; Kotake T; Akaza H; Hinotsu S; Kakizoe T
    Jpn J Clin Oncol; 1998 Aug; 28(8):497-501. PubMed ID: 9769784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shorter interval between cycles of cyclophosphamide, doxorubicin, cisplatin using recombinant human granulocyte colony-stimulating factor for urothelial cancer--phase I/II study.
    Yoshida O; Kakehi Y; Arai Y; Tomoyoshi T; Okada Y; Matsuda T; Mikami O; Fukuyama T; Hida S; Okabe T
    Int J Urol; 1995 Nov; 2(5):316-21. PubMed ID: 8749950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma.
    McCaffrey JA; Hilton S; Mazumdar M; Sadan S; Heineman M; Hirsch J; Kelly WK; Scher HI; Bajorin DF
    J Clin Oncol; 1997 Jun; 15(6):2449-55. PubMed ID: 9196161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [MEP (methotrexate, etoposide and cisplatin) and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced uroepithelial cancer--a preliminary report of MEP as second line chemotherapy for recurrence after M-VAC].
    Seguchi T; Nakano E; Miki T; Kondoh M; Nishimura K; Nakamura N; Okuyama A
    Gan To Kagaku Ryoho; 1994 Jan; 21(1):59-65. PubMed ID: 8291917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse events of MVAC chemotherapy in patients with advanced urothelial cancer of the bladder.
    Maeda T; Takahashi A; Hirobe M; Honma I; Masumori N; Itoh N; Tsukamoto T
    Hinyokika Kiyo; 2007 Apr; 53(4):213-9. PubMed ID: 17515069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Escalated M-VAC chemotherapy and recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in patients with advanced urothelial tract tumors.
    Sternberg CN; de Mulder PH; van Oosterom AT; Fossa SD; Giannarelli D; Soedirman JR
    Ann Oncol; 1993 May; 4(5):403-7. PubMed ID: 8353075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of timing of granulocyte-colony stimulating factor administration on leukopenia induced by systemic chemotherapy in patients with non-small-cell lung cancer--multi-center randomized crossover study].
    Katakami N; Hasegawa T; Umeda B; Adachi S; Ishii N; Takada Y; Tsubota N; Nakano K; Tamura R; Nakai H
    Nihon Kyobu Shikkan Gakkai Zasshi; 1996 May; 34(5):520-8. PubMed ID: 8753109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer--analysis of efficacy and toxicity].
    Igawa M; Kadena H; Ohkuchi T; Ueda M; Usui T
    Nihon Hinyokika Gakkai Zasshi; 1991 Oct; 82(10):1627-36. PubMed ID: 1770701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.